The evaluation and treatment of retroperitoneal sarcomas are challenging because the tumors are relatively rare and frequently present with advanced disease in an anatomically complex location.
Methods:
We reviewed the literature on experience in the management of retroperitoneal sarcomas, and we present our own experience in the treatment of these tumors.
Results:
The identification of prognostic factors other than the adequacy of resection has been inconsistent. Due to a lack of associated symptoms, retroperitoneal sarcomas smaller than 5 cm are rare. Computed tomography is the most useful tool in the evaluation of retroperitoneal tumors. Surgery, radiation therapy, and chemotherapy are treatment options, but the most important factor in the treatment of primary tumors is complete surgical resection. The role of neoadjuvant and adjuvant therapies is not defined and should be considered within the context of clinical trials.
Conclusions:
Early referral of patients with retroperitoneal soft tissue tumors will help to ensure that they will receive the benefits of multidisciplinary evaluation and treatment of their disease and ready access to clinical trials.
References
1.
JemalA., TiwariR.C., MurrayT.. Cancer statistics, 2004.CA Cancer J Clin.2004; 54: 8–29.
HelmanL.J., MeltzerP.. Mechanisms of sarcoma development.Nat Rev Cancer.2003; 3: 685–694.
4.
LewisJ.J., LeungD., WoodruffJ.M.. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution.Ann Surg.1998; 228: 355–365.
5.
StoeckleE., CoindreJ.M., BonvalotS.. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.Cancer.2001; 92: 359–368.
6.
FerrarioT., KarakousisC.P.. Retroperitoneal sarcomas: grade and survival.Arch Surg.2003; 138: 248–251.
7.
AlvarengaJ.C., BallA.B., FisherC.. Limitations of surgery in the treatment of retroperitoneal sarcoma.Br J Surg.1991; 78: 912–916.
8.
DaltonR.R., DonohueJ.H., MuchaP.Jr,. Management of retroperitoneal sarcomas.Surgery.1989; 106: 725–733.
9.
JaquesD.P., CoitdG, HajduS.I.. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum.Ann Surg.1990; 212: 51–59.
10.
HassanI., ParkS.Z., DonohueJ.H.. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience.Ann Surg.2004; 239: 244–250.
11.
KarakousisC.P., GerstenbluthR., KontzoglouK.. Retroperitoneal sarcomas and their management.Arch Surg.1995; 130: 1104–1109.
12.
ZornigC., WehH.J., KrullA.. Retroperitoneal sarcoma in a series of 51 adults.Eur J Surg Oncol.1992; 18: 475–480.
13.
PirayeshA., CheeY., HelliwellT.R.. The management of retroperitoneal soft tissue sarcoma: a single institution experience with a review of the literature.Eur J Surg Oncol.2001; 27: 491–497.
14.
McGrathP.C., NeifeldJ.P., LawrenceW.Jr,. Improved survival following complete excision of retroperitoneal sarcomas.Ann Surg.1984; 200: 200–204.
15.
StormF.K., EilberF.R., MirraJ.. Retroperitoneal sarcomas: a reappraisal of treatment.J Surg Oncol.1981; 17: 1–7.
16.
HeslinM.J., Cordon-CardoC., LewisJ.J.. Ki-67 Detected by MIB- 1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma.Cancer.1998; 83: 490–497.
17.
CheifetzR., CattonC., KandelR.. Recent progress in the management of retroperitoneal sarcoma.Sarcoma.2001; 5: 17–26.
18.
HeslinM.J., LewisJ.J., NadlerE.. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management.J Clin Oncol.1997; 15: 2832–2839.
19.
KilkennyJWIII, BlandK.I., CopelandEMIII. Retroperitoneal sarcoma: the University of Florida experience.J Am Coll Surg.1996; 182: 329–339.
MakelaJ., KiviniemiH., LaitinenS.. Prognostic factors predicting survival in the treatment of retroperitoneal sarcoma.Eur J Surg Oncol.2000; 26: 552–555.
26.
WangT.Y., LoS.S., SuC.H.. Surgical management of primary retroperitoneal sarcoma.Chin Med J (Taipei).1996; 58: 177–182.
27.
SenagoreA.J., MadboulyK.M., FazioV.W.. Advantages of laparoscopic colectomy in older patients.Arch Surg.2003; 138: 252–256.
28.
SandersT.G., ParsonsTWIII. Radiographic imaging of musculoskeletal neoplasia.Cancer Control.2001; 8: 221–231.
29.
GranstromP., UngerE.. MR imaging of the retroperitoneum.Magn Reson Imaging Clin N Am.1995; 3: 121–142.
30.
WindhamT.C., PearsonA.S., SkibberJ.M.. Significance and management of local recurrences and limited metastatic disease in the abdomen.Surg Clin North Am.2000; 80: 761–774, xii.
31.
ShibataD., LewisJ.J., LeungD.H.. Is there a role for incomplete resection in the management of retroperitoneal liposarcomas?J Am Coll Surg.2001; 193: 373–379.
GlennJ., SindelarW.F., KinsellaT.. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum.Surgery.1985; 97: 316–325.
37.
PistersP.W., BalloM.T., FenstermacherM.J.. Phase I Trial of Preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.J Clin Oncol.2003; 21: 3092–3097.
38.
SindelarW.F., KinsellaT.J., ChenP.W.. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial.Arch Surg.1993; 128: 402–410.
39.
JonesJ.J., CattonC.N., O'SullivanB.. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachy-therapy for retroperitoneal sarcoma.Ann Surg Oncol.2002; 9: 346–354.
40.
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration.Lancet.1997; 350: 1647–1654.
41.
SpiraA.I., EttingerD.S.. The use of chemotherapy in soft-tissue sarcomas.Oncologist.2002; 7: 348–359.
42.
FrustaciS., GherlinzoniF., De PaoliA.. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.J Clin Oncol.2001; 19: 1238–1247.
43.
FrustaciS., De PaoliA., BidoliE.. Ifosfamide in the adjuvant therapy of soft tissue sarcomas.Oncology.2003; 65(Suppl 2): 80–84.
44.
MaurelJ., FraJ., Lopez-PousaA.. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas. a phase II trial by the Spanish Group for Research on Sarcomas (GEIS).Cancer.2004; 100: 1498–1506.
45.
Le CesneA., JudsonI., CrowtherD.. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulo-cyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.J Clin Oncol.2000; 18: 2676–2684.
46.
LopezM., ViciP., Di LauroL.. Increasing single epirubicin doses in advanced soft tissue sarcomas.J Clin Oncol.2002; 20: 1329–1334.
47.
PatelS.R., Vadhan-RajS., BurgessM.A.. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifos-famide in patients with sarcomas.Am J Clin Oncol.1998; 21: 317–321.
48.
WordenF.P., TaylorJ.M.G., BiermanJ.S.. A randomized phase II evaluation of standard dose ifosfamide (IFOS) plus doxorubicin (DOX) versus high dose ifosfamide plus DOX in patients with high-grade soft tissue sarcomas.Proc Annu Meet Am Soc Clin Oncol.2003; 22: 817. Abstract 3284.
49.
PotterD.A., GlennJ., KinsellaT.. Patterns of recurrence in patients with high-grade soft-tissue sarcomas.J Clin Oncol.1985; 3: 353–366.
50.
BrennanM.F., LewisJ.J., eds. Diagnosis and Management of Soft Tissue Sarcoma.London: Martin Dunitz, Florence, Ky. Distributed in the USA by Taylor & Francis; 2002.
51.
BillingsleyK.G., LewisJ.J., LeungD.H.. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma.Cancer.1999; 85: 389–395.
52.
SawyerM., BramwellV.. The treatment of distant metastases in soft tissue sarcoma.Semin Radiat Oncol.1999; 9: 389–400.
53.
van GeelA.N., PastorinoU., JauchK.W.. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients.Cancer.1996; 77: 675–682.
54.
BillingsleyK.G., BurtM.E., JaraE.. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival.Ann Surg.1999; 229: 602–612.
55.
SaltzmanD.A., SnyderC.L., FerrellK.L.. Aggressive metastasec-tomy for pulmonic sarcomatous metastases: a follow-up study.Am J Surg.1993; 166: 543–547.
BrennanM.F., AlektiarK.M., MakiR.G.. Soft tissue sarcoma. In: DeVitaV.T.Jr, HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.6th ed.Philadelphia, Pa: Lippincott Williams & Wilkins;2001.
59.
EliasA., RyanL., SulkesA.. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.J Clin Oncol.1989; 7: 1208–1216.
60.
AntmanK.H., CrowleyJ., BalcerzakS.P.. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.J Clin Oncol.1993; 11: 1276–1285.
61.
AntmanK.H., RyanL., EliasA.. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.J Clin Oncol.1989; 7: 126–131.
62.
van OosteromA.T., MouridsenH.T., NielsenO.S.. Results of randomized studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.Eur J Cancer.2002; 38: 2397–2406.
63.
HensleyM.L., MakiR., VenkatramanE.. Gemcitabine and doc- etaxel in patients with unresectable lieomyosarcoma: results of a phase II trial.J Ciin Oncol.2002; 20: 2824–2831.
64.
LeuK.M., OstruszkaL.J., ShewachD.. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.J Clin Oncol.2004; 22: 1706–1712.
65.
ThallP.F., WathenJ.K., BekeleB.N.. Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.Stat Med.2003; 22: 763–780.
66.
GieschenH.L., SpiroI.J., SuitH.D.. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma.Int J Radiat Oncol Biol Phys.2001; 50: 127–131.
